Nuclear Medicine Market
Report ID: SQMIG35I2285
Report ID: SQMIG35I2285
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35I2285 |
Region:
Global |
Published Date: July, 2025
Pages:
185
|Tables:
146
|Figures:
78
Global Nuclear Medicine Market size was valued at USD 9.09 Billion in 2023 poised to grow between USD 10.94 Billion in 2024 to USD 12.11 Billion in 2025, growing at a CAGR of USD 27.3 Billion by 2033 in the forecast period 10.7%.
The increasing prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions is a primary driver of the global nuclear medicine market. These illnesses require advanced diagnostic techniques for early detection and effective treatment planning. Nuclear medicine, particularly PET and SPECT imaging, enables visualization of biological processes at the molecular and cellular level, allowing clinicians to detect abnormalities before structural changes occur. This precision is especially critical in oncology for tumor detection, staging, and monitoring treatment response. As chronic diseases continue to rise globally due to aging populations and lifestyle changes, the demand for nuclear medicine is expected to grow substantially.
Rapid technological advancements in radiopharmaceuticals and imaging equipment are a key trend driving the global nuclear medicine sector. Innovations such as hybrid imaging systems (e.g., PET/CT and SPECT/CT), new radioisotopes, and targeted radiotracers have significantly enhanced diagnostic accuracy and therapeutic potential. These improvements allow for better resolution, shorter imaging times, and lower radiation doses, increasing both patient safety and comfort. Additionally, the development of theranostics—combining diagnostics and therapy using the same molecule—has revolutionized personalized medicine. These innovations have not only expanded clinical applications but also increased adoption by healthcare providers, supporting the market’s continuous evolution.
How does AI Contribute to Better Treatment Planning in Nuclear Medicine?
Artificial Intelligence (AI) is significantly impacting the global nuclear medicine market by enhancing imaging accuracy, diagnostic speed, and workflow efficiency. AI algorithms can analyze complex PET and SPECT scans with high precision, enabling early and more accurate detection of diseases such as cancer and Alzheimer’s. This leads to improved patient outcomes and optimized treatment planning. AI also automates time-consuming tasks like image reconstruction and segmentation, reducing clinician workload and turnaround times. A notable development is GE HealthCare's integration of AI into its molecular imaging systems, which streamlines image processing and supports clinical decision-making—ultimately accelerating the adoption of nuclear medicine in modern healthcare.
In February 2024, GE HealthCare partnered with Nuance Communications to embed AI‑driven analysis into medical imaging tools—enhancing PET/SPECT diagnostic workflows. This collaboration enables faster, more accurate scan interpretation, reducing clinician workload and improving patient throughput, thereby accelerating AI-driven nuclear medicine adoption.
To get more insights on this market click here to Request a Free Sample Report
The global nuclear medicine market is segmented based on product, application, end use, and region. In terms of products, the market is divided into diagnostics and therapeutics. Based on application, the market is grouped into cardiology, neurology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumor, pulmonary scans, urology, and others. Based on end use, the market is trifurcated into hospitals, diagnostic centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.
Why do Diagnostic Products hold a Dominant Position in the Nuclear Medicine Market?
Based on the global nuclear medicine market forecast, diagnostic products dominate the industry are witnessing rapid innovation, particularly in PET and SPECT imaging technologies. These advancements allow early and accurate detection of diseases like cancer and neurological disorders. The dominance of diagnostic products stems from their critical role in non-invasive, real-time disease monitoring and increasing global demand for precision medicine. Their widespread clinical adoption and continual technological upgrades drive their leading position in the nuclear medicine landscape.
Therapeutics products are poised to become the fastest-growing segment in the global nuclear medicine market, driven by the rise of targeted radiopharmaceutical therapies that enable precise tumor eradication with minimal side effects. As more FDA-approved agents emerge, demand grows—propelling rapid expansion in therapeutic applications and investment.
What are the Advantages of Using Nuclear Medicine for Urological Malignancies?
Urology applications dominate the global nuclear medicine market and are advancing through innovations like PSMA-targeted PET imaging and radioligand therapy, primarily for prostate cancer. These tools enable early, accurate detection, and targeted treatment with minimal side effects. Urology dominates the market due to the high global prevalence of prostate cancer, rising awareness, and the proven effectiveness of nuclear medicine in diagnosing and treating urological malignancies with precision.
Endocrine tumor applications are the fastest-growing segment in the global nuclear medicine market due to rising cases of thyroid and neuroendocrine tumors. Innovations in theranostics, like ^68Ga-DOTATATE and ^177Lu-DOTATATE, enable precise targeting and treatment. The effectiveness of these radiopharmaceuticals is driving clinical adoption, improving patient outcomes, and accelerating segment growth.
To get detailed segments analysis, Request a Free Sample Report
How does the Presence of Key Industry Players Impact the Market in North America?
As per the global nuclear medicine market analysis, North America leads the industry due to advanced healthcare infrastructure, high adoption of innovative imaging technologies, and strong presence of key industry players. The region benefits from increased R&D investments, supportive regulatory frameworks, and rising prevalence of chronic conditions like cancer and cardiovascular diseases. Additionally, growing awareness of early diagnostic tools and the availability of FDA-approved radiopharmaceuticals further drive market expansion across the U.S. and Canada.
US Nuclear Medicine Market
The United States is the dominant contributor to North America’s nuclear medicine market, driven by a strong healthcare system, substantial R&D funding, and a high rate of chronic diseases like cancer. The presence of leading companies, such as GE HealthCare and Cardinal Health, enhances technological adoption. Additionally, frequent FDA approvals and clinical trials for novel radiopharmaceuticals support rapid innovation, making the U.S. a global hub for nuclear medicine advancements.
Canada Nuclear Medicine Market
Canada’s nuclear medicine market contribution is steadily growing due to government support, academic research, and expanding use of molecular imaging in oncology and cardiology. The country is a global leader in radioisotope production, particularly with the TRIUMF facility. Efforts to decentralize radiopharmaceutical access and strengthen healthcare infrastructure are improving diagnostic and therapeutic capabilities, positioning Canada as a vital player in North America’s nuclear medicine ecosystem.
What are the Three Key Factors Driving Growth in Asia Pacific’s Nuclear Medicine Market?
Asia Pacific is emerging as a fast-growing region in the global nuclear medicine market, driven by rising healthcare investments, increasing cancer incidence, and expanding access to advanced imaging technologies. Countries like China, Japan, and India are boosting radiopharmaceutical production and infrastructure. Government initiatives, public-private partnerships, and a growing emphasis on early disease detection are accelerating market growth, making Asia Pacific a key hub for both diagnostic and therapeutic nuclear medicine advancements.
Japan Nuclear Medicine Market
Japan is a major contributor to the Asia Pacific nuclear medicine market, supported by its advanced healthcare system, technological innovation, and high adoption rates of PET and SPECT imaging. The country invests heavily in R&D for novel radiopharmaceuticals and theranostics, particularly targeting cancer and neurological disorders. Japan’s aging population and rising chronic disease prevalence drive demand, while collaborations between government, academia, and industry foster continuous advancements in nuclear medicine applications.
South Korea Nuclear Medicine Market
South Korea’s nuclear medicine market is rapidly growing due to strong government support, increasing cancer cases, and expanding healthcare infrastructure. The country focuses on developing innovative radiopharmaceuticals and molecular imaging technologies, enhancing diagnostic and therapeutic capabilities. South Korea’s well-established biotech sector and investment in clinical trials accelerate adoption of advanced nuclear medicine practices. These efforts position South Korea as a significant and emerging player in the global nuclear medicine landscape.
What Demographic Trend in Europe is Increasing Demand for Nuclear Medicine?
Europe holds a significant share of the global nuclear medicine market due to its strong healthcare infrastructure, rising geriatric population, and increasing cancer prevalence. Countries like Germany, France, and the UK lead in radiopharmaceutical usage and research. The region benefits from government-funded healthcare systems and active collaborations between academic institutions and industry. Additionally, ongoing investments in PET and SPECT technologies support Europe’s growing role in diagnostic and therapeutic nuclear medicine applications.
Germany Nuclear Medicine Market
Germany plays a leading role in Europe’s nuclear medicine market, driven by its advanced healthcare infrastructure, strong academic research, and early adoption of PET and SPECT imaging technologies. The country is home to numerous radiopharmaceutical manufacturing facilities and clinical trial centers. Government funding and collaborations between universities and biotech firms further boost innovation, making Germany a key hub for both diagnostic and therapeutic nuclear medicine applications in Europe.
France Nuclear Medicine Market
France contributes significantly to the Europe’s nuclear medicine market through robust public healthcare support, active clinical research, and growing cancer diagnosis demand. Institutions like the Curie Institute and partnerships with nuclear technology firms enhance radiopharmaceutical innovation. France’s increasing investments in theranostics and expansion of PET/CT imaging services across hospitals drive its market share, with an emphasis on precision medicine and personalized cancer therapies using advanced nuclear technologies.
Italy Nuclear Medicine Market
Italy is emerging as a strong contributor to the Europe’s nuclear medicine market, with increasing applications in oncology and cardiology diagnostics. The country benefits from a well-organized healthcare system and growing adoption of advanced imaging modalities. Italian universities and research institutions are actively involved in clinical trials and isotope development. Government initiatives to modernize medical imaging infrastructure further support Italy’s expanding presence in the European and global nuclear medicine markets.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Nuclear Medicine Market Drivers
Increasing Prevalence of Cancer
Technological Advancements in Radiopharmaceuticals
Nuclear Medicine Market Restraints
Regulatory and Safety Concerns
Limited Availability of Radiopharmaceuticals
Request Free Customization of this report to help us to meet your business objectives.
The global nuclear medicine market outlook is highly competitive, with key players like GE HealthCare, Siemens Healthineers, Cardinal Health, and Curium leading innovation. Companies focus on strategic partnerships, product launches, and expanding radiopharmaceutical portfolios to strengthen market position. For example, GE HealthCare invests in AI integration for imaging solutions, while Cardinal Health emphasizes supply chain optimization and expanding its radiopharmaceutical manufacturing capacity, driving growth and enhancing global reach in this evolving market.
As per the global nuclear medicine industry analysis, the startup landscape is rapidly evolving, driven by innovations in targeted radiopharmaceuticals, advanced imaging agents, and personalized therapies. Emerging companies focus on improving diagnostic accuracy and therapeutic efficacy through novel compounds and technology platforms. Strategic collaborations with academic institutions and established industry leaders accelerate development and commercialization. These startups play a vital role in expanding nuclear medicine’s clinical applications and enhancing patient outcomes worldwide.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global nuclear medicine industry is experiencing robust growth driven primarily by the increasing prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions. These illnesses demand advanced diagnostic techniques like PET and SPECT imaging, which enable early detection and precise treatment planning. The market also benefits from rapid technological advancements, including hybrid imaging systems, novel radiopharmaceuticals, and theranostics, which enhance diagnostic accuracy and therapeutic outcomes, promoting personalized medicine.
Additionally, AI integration improves imaging efficiency and accuracy, further accelerating market adoption. Regional insights reveal that North America and Asia Pacific lead growth due to strong healthcare infrastructure and rising disease incidence. Overall, continued innovation, expanding clinical applications, and increasing demand position the global nuclear medicine market strategies as a vital pillar in modern healthcare.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 9.09 Billion |
| Market size value in 2033 | USD 12.11 Billion |
| Growth Rate | USD 27.3 Billion by 2033 in the forecast period 10.7% |
| Base year | 2024 |
| Forecast period | 10 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Nuclear Medicine Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Nuclear Medicine Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Nuclear Medicine Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Nuclear Medicine Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Nuclear Medicine Market size was valued at USD 9.09 Billion in 2023 poised to grow between USD 10.94 Billion in 2024 to USD 12.11 Billion in 2025, growing at a CAGR of USD 27.3 Billion by 2033 in the forecast period 10.7%.
The global nuclear medicine market outlook is highly competitive, with key players like GE HealthCare, Siemens Healthineers, Cardinal Health, and Curium leading innovation. Companies focus on strategic partnerships, product launches, and expanding radiopharmaceutical portfolios to strengthen market position. For example, GE HealthCare invests in AI integration for imaging solutions, while Cardinal Health emphasizes supply chain optimization and expanding its radiopharmaceutical manufacturing capacity, driving growth and enhancing global reach in this evolving market. 'GE HealthCare (USA)', 'Siemens Healthineers (Germany)', 'Cardinal Health (USA)', 'Curium (France)', 'Jubilant Life Sciences (India)', 'Lantheus Holdings (USA)', 'Bracco Imaging (Italy)', 'Philips Healthcare (Netherlands)', 'Advanced Accelerator Applications (France)', 'Nihon Medi-Physics (Japan)', 'Spectrum Pharmaceuticals (USA)', 'Ion Beam Applications (IBA) (Belgium)', 'Eckert & Ziegler (Germany)', 'ABX Advanced Biomedical Compounds (Germany)', 'Sofie Biosciences (USA)'
The rising global incidence of cancer significantly drives the nuclear medicine market. Nuclear imaging techniques like PET and SPECT enable early tumor detection, accurate staging, and treatment monitoring. Growing awareness and demand for precision diagnostics in oncology are boosting adoption rates, fueling market expansion worldwide.
Rising Adoption of Theranostics: Theranostics, combining diagnostic imaging with targeted radiopharmaceutical therapy, is rapidly transforming the global nuclear medicine market trends. By enabling personalized treatment plans through precise tumor detection and simultaneous therapy, it drives demand for innovative radiotracers and expands clinical applications, particularly in oncology, enhancing patient outcomes and market growth.
How does the Presence of Key Industry Players Impact the Market in North America?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
